Dave Briggs, a principal scientist at Avid Bioservices, will examine these production hurdles during an upcoming Xtalks webinar on September 24, 2026. The session focuses on the intersection of upstream cell line development and downstream purification, highlighting how early process control directly influences the reproducibility of final drug products. By addressing variables such as antigen binding strength and glycosylation patterns, manufacturing teams can mitigate the inconsistencies that frequently disrupt large-scale ADC programs.
Optimizing Antibody Quality to Streamline ADC Manufacturing
The precision of antibody-drug conjugates hinges on the integrity of the monoclonal antibody component, a factor that often dictates the success of downstream payload attachment. As oncology programs scale toward commercial production, maintaining consistent structural stability remains a primary challenge for developers aiming to reduce conjugation risks and improve clinical performance.
Participants will gain insights into how strategic process characterization minimizes variability as programs move from clinical development to commercial manufacturing. Through a detailed success story, the presentation illustrates how targeted upstream optimizations can resolve conjugation inefficiencies. The discussion serves as a practical guide for development teams seeking to leverage specialized CDMO support to stabilize production workflows and ensure the reliable delivery of potent cytotoxic payloads.
Comments (0)
No comments yet. Be the first!